Skip to Content

Deferasirox Pregnancy and Breastfeeding Warnings

Deferasirox is also known as: Exjade, Jadenu, Jadenu Sprinkle

Medically reviewed on May 29, 2018

Deferasirox Pregnancy Warnings

Animal studies showed decreased offspring viability and renal anomalies in male offspring at exposures about equal to or less than the recommended human exposure. No fetal effects were noted in a different animal model at doses equivalent to the human dose. There are no controlled data in human pregnancy.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: C
US FDA pregnancy category: C

See references

Deferasirox Breastfeeding Warnings

This drug was rapidly and extensively secreted into maternal milk in animal studies, at higher concentrations than in maternal plasma.

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-No data are available on the presence of this drug or its metabolites in human milk, effects on the breastfed infant, or effects on milk production.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide